Karim Dabbagh joined Second Genome in 2014. Prior, he served as Vice President of R&D at Pfizer where he led the Immunoregulation department, an R&D group focused on innovative approaches to elicit homeostatic immune responses for the treatment of immune related disorders. At Pfizer, he also led External R&D Innovation for Immunology, Neurosciences and Cardiovascular/Metabolic Therapy Areas. Before joining Pfizer, Karim was the founder of Modus BioMedicine, a biotechnology company focused on treatments for transplantation and autoimmune disease. Leading to that, Karim spent nine years at Roche in Inflammation Discovery Research. Karim obtained his PhD in Biochemistry from University College, London and his BSc (Hons) in Biotechnology from Imperial College, London. He completed postdoctoral fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and at Stanford University where he worked on elucidating the role played by the microbiome in the hygiene hypothesis.
Dr. Sarangarajan is a recognized R&D leader. As the CSO and SVP Clinical and Translational Sciences at BERG, he led multi-functional teams integrating biology, technology, and artificial intelligence analytics in the development of a multi-omic, biology-based platform for the discovery of disease-specific targets, therapeutic discovery, and diagnostics development. Ranga obtained his Ph.D., in Pharmaceutical Sciences from the University of Cincinnati and a B.S., in Pharmacy from Maharaja Sayajirao University.
Metabolomics in Drug Development